No BRCAl germline mutation in a family with uterine papillary serous carcinoma: A case report

The purpose of the study was to examine BRCA1 germline mutation and its relationship to BRCA1 expression in two patients, a mother and a daughter, both diagnosed with uterine papillary serous carcinoma (UPSC). DNA was screened for BRCA1 and BRCA2 germline mutations common in the Jewish population (185delAG, 5382insC, and 6174delT) by PCR-based assay and with a protein truncation test (PTT) to detect mutation in exon 11 of BRCA1 and exons 10 and 11 of BRCA2. BRCA1 expression in fixed tumor tissues was assessed by immunocytochemistry (IHC). No germline mutation in either BRCAI or BRCA2 gene was found in the two patients. Both samples showed reduced levels of BRCAI expression. Taken together, these results suggest that undetected or unscreened for germline mutation may be associated with occurrence of this rare tumor type in two members of the same family. Alternatively, an epigenetic mechanism such as BRCA1 promoter hypermethylation may be responsible for reduced expression of BRCA1 in the absence of DNA mutations.

Uterine papillary serous carcinoma; BRCAl; BRCA2; Immunocytochemistry

[1] Carcangiu M. L., Chambers J. T.: "Uterine papillary serous carcinoma: A study on I 08 cases with emphasis on the prognostic signif icance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma". Gynecol. Oneal., 1992, 47, 298.

[2] Hendrickson M., Ross J., Eifel P., Martinez A., Kempson R.: "Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma". Am. J. Surg. Pathol., 1982, 6, 93.

[3] Homreich G., Beller U., Lavie 0., Renbaum P., Cohen Y., LevyLahad E.: "Is uterine serous papillary carcinoma a BRCAlrelated disease? Case report and review of the literature". Gynecol. Oneal., 1999, 75, 300.

[4] Lavie O., Homreich G., Ben Arie A., Renbaum P., Levy-Lahad E., Beller U.: "BRCAl germline mutations in women with uterine serous papillary carcinoma". Obstet. Gynecol., 2000, 96, 28.

[5] Goshen R.,C hu W.,E lit L.,P al T., Hakimi J.,A ckerman I. et al.: "Is uterine serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?". Gynecol. Oneal., 2000, 79, 477.

[6] Hakanssom S.,J ohansson 0.,J ohasson U.,S ellbergG .,L oman N., Gerdes A-M. et al.: "Moderate frequency of BRCAl and BRCA2 gem-line mutations in Scandinavian familial breast cancer". Am. J. Hum. Genet., 1997, 60, 1068.

[7] Van der Luijt R., Khan P. M., Vasen H., van Leeuwen C., Tops C., Roest P. et al.: "Rapid detection of translating-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test". Genomics, 1994, 20, 1.

[8] Wilson C. A., Ramos L., Villasenor R., Anders K., Press M. F., Clarke K. et al.: "Localization of human BRCAI and its loss in high-grade, non-inherited breast carcinomas". Nat. Genet., 1999, 21, 236.

[9] Sherman M. E., Bur M. E., Kurman R. J., Enomoto T., Sakata M., Tanizawa O., Ueshima H.: "p53 in endometrial cancer and its putative precursors:evidence for diverse pathways of tumorigenesis". Hum. Pathol., 1995, 26, 1268.

[10] Berchuck A., Heron K. A., Carney M. E., Lancaster J. M., Fraser E.G., Vinson V. L. et al.: "Frequency of germline and somatic BRCAI mutations in ovarian cancer". Clin. Cancer Res., 1998, 4, 2433.

[11] Zheng W., Luo F., Lu J. J., Baltayan A., Press M. F., Zhang Z-F., Pike M. C.: "Reduction of BRCAI expression in sporadic ovarian cancer". Gynecol. Oncol., 2000, 76, 294.

[12] Baldwin R. L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., Karlam B. Y.: "BRCAI promoter region hypermethylation in ovarian carcinoma: a population based study". Cancer Res., 2000, 60, 5329.